2
Participants
Start Date
October 31, 2015
Primary Completion Date
September 30, 2017
Study Completion Date
September 30, 2017
Vigil
Vigil™ 1 x 10e7 cells via intradermal injection on Day 1, 15, 29, 43 and then every 3 weeks thereafter for a minimum of 4 administrations and a maximum of 9 administrations (depending on the quantity of Vigil™ manufactured from surgical specimens)
Pembrolizumab
Pembrolizumab 2mg/kg by intravenous infusion over 30 minute starting on day 43 and every 3 weeks thereafter
Mary Crowley Medical Research Centers, Dallas
Texas Oncology P.A., Texas Cancer Center, Abilene
Cancer Care Northwest, Spokane
Lead Sponsor
Gradalis, Inc.
INDUSTRY